Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
SCIENTIFIC RESULTS OF 
TRANS2CARE PROJECT 
Lovro Žiberna, PhD MPharm 
LP – University of Trieste 
Trieste, September 11, 2...
1.cell biology, membrane transport 
2.statistics, chemometrics 
3.transcriptome analysis 
4.analytical chemistry 
5.geneti...
CLINICIANS 
BASIC SCIENTISTS 
TECHNO- LOGISTS 
Unmet medical needs 
Scientific understanding and possible solutions 
Techn...
PP2 
priondiseases 
PP10 
diagnosticmAbs 
PP6 
nefrotoxicitypost-coronarydilation 
PP6, PP12 
plasma free bilirubin 
LP 
m...
0 
2 
4 
6 
8 
10 
12 
14 
LP 
PP1 
PP2 
PP3 
PP4 
PP5 
PP6 
PP7 
PP8 
PP9 
PP10 
PP11 
PP12 
number of publications 
scie...
>1 T2C partner (networking): 
20.7 % of all scientific papers 
37.8 % of all conference contributions 
0 
5 
10 
15 
20 
2...
pre-disease screening 
21stcentury medicine 
focused on identifying the window of opportunity before the full development ...
OBESITY AND OVERWEIGHT 
►how specific dietary compounds intake modulates the gene expression of the adipokines (nutrigenom...
OBESITY AND OVERWEIGHT 
►Identification of early biomarkers of metabolic imbalance in healthy subjects 
►bilirubin as a pr...
CANCER AND LIFESTYLES 
“localadjuvanttherapy”byanthocyanins-enricheddietforcoloncancerpatients 
focusonmembranetransport...
CANCER AND LIFESTYLES 
newhistologicalbiomarker(expressionofbilitranslocase)forthediagnosisofkidneycancer 
developmentof...
NEURODEGENERATION 
large-scaletranscriptionalprofilingofbrainsfromprion-infectedmacaques,whichareanexcellentmodelforhuman...
CARDIOVASCULAR DISEASES 
interventionalcardiologyiodinecontrast-inducednephropathy 
detectionofearlysignsofnephropathyb...
COELIAC DISEASE 
doubleimmunofluorescenceanalysisallowedtheearlydiagnosisinsubjectsathighriskofceliacdisease 
pre-diseas...
BONE HEALTH 
improvinglife-spanoforthopedicimplantsbythepreventionofprostheticjointinfections 
incorporation/immobilizat...
DIAGNOSTIC BIOMARKERS 
novelmethodforthedetectionoffreebilirubininhumanserum(non-routineclinicalmeasurementofthebioactive...
INTELLECTUAL PROPERTY 
 open innovation 
 “Think before you publish.”  “Perhaps, patent?” 
 creation of a necessary sc...
Trans2Care workpackages 
Embedding training in the network’s activitiesWP6TECH TRANSFER 
WP2 
PREPARATORY ACTIVITY 
WP7 
S...
OTHER SCIENTIFIC ACTIVITIES 
Focus on knowledge sharing and developing integrated skills 
•acting as reviewers of original...
Progetto Rete Transregionale per l ’ innovazione ed il Trasferimento Tecnologico per il 
Miglioramento della Sanità finanz...
Upcoming SlideShare
Loading in …5
×

SCIENTIFIC RESULTS OF TRANS2CARE PROJECT - Lovro Ziberna

917 views

Published on

SCIENTIFIC RESULTS OF TRANS2CARE PROJECT
Lovro Žiberna, PhD MPharm
LP – University of Trieste

Published in: Healthcare
  • Be the first to comment

  • Be the first to like this

SCIENTIFIC RESULTS OF TRANS2CARE PROJECT - Lovro Ziberna

  1. 1. SCIENTIFIC RESULTS OF TRANS2CARE PROJECT Lovro Žiberna, PhD MPharm LP – University of Trieste Trieste, September 11, 2014 Final conference
  2. 2. 1.cell biology, membrane transport 2.statistics, chemometrics 3.transcriptome analysis 4.analytical chemistry 5.genetics, clinical markers 6.IP management 7.clinical chemistry in intensive care 8.electrochemistry 9.anti-microbial peptides 10.IHC, clinical specimens 11.antibody production, stem cells 12.biocompatible materials 13.genetics, clinical markers THE SCIENCE OF OUR Partners can we link local Institutions by research synergies?
  3. 3. CLINICIANS BASIC SCIENTISTS TECHNO- LOGISTS Unmet medical needs Scientific understanding and possible solutions Technical solutions TRANS2CARE at start 1.CARDIOVASCULAR DISEASES 2.NEURODEGENERATIVE DISEASES 3.CANCER 4.OBESITY 5.ORTHOPAEDIC DISEASES 6.AUTOIMMUNE DISEASES 1.Nephrotoxicityfollowingcoronarystent 2.Priondiseases 3.Nutrigenomicsof obesity 4.R&D on implantslifespan 5.Bio-availabilityand bioactivityof dietarypolyphenols 6.Coeliacdisease 1.Computational and statistical support 2.Analytical chemistry 3.Research antibodies 4.Nanoparticles, biosensors 5.Tech transfer, IP protection
  4. 4. PP2 priondiseases PP10 diagnosticmAbs PP6 nefrotoxicitypost-coronarydilation PP6, PP12 plasma free bilirubin LP membrane transport PP9 anti- transglutaminaseantibodiesin plasma PP4 Klothoproteinin plasma PP7 Electro-chemicalbiosensors PP3 Analyticalchemistry br NGAL cytotox br Ab Klo Ab- BTL Ab- prion PP1 chemometrics BTL prion PP5 training techtransfer IP PP8 BTL in plant anti-microb. peptides PP11 biomaterialsfor implants AMP Ab- BTL IDEAS PRODUCTS technical tools pre-clinical studies clinical applications
  5. 5. 0 2 4 6 8 10 12 14 LP PP1 PP2 PP3 PP4 PP5 PP6 PP7 PP8 PP9 PP10 PP11 PP12 number of publications scientific papers/bookchapters active contributions atthe scientificconference papers in preparation SCIENTIFIC OUTPUT OF T2C RESEARCHERS 2.38 scientific papers/researcher 3.77 active conference contributions/ researcher
  6. 6. >1 T2C partner (networking): 20.7 % of all scientific papers 37.8 % of all conference contributions 0 5 10 15 20 25 30 scientific papers/book chapters active contributions at the scientificconference 1 >1 6 20 23 29 SCIENTIFIC OUTPUT OF T2C RESEARCHERS
  7. 7. pre-disease screening 21stcentury medicine focused on identifying the window of opportunity before the full development of pathology (REVERSIBLE CHANGES) healthy aging disease diagnosis and causative treatment 20thcentury medicine focused on diagnostics (after pathology fully developed) and treatment: pharmacology and/or surgery chronic treatment to keep body close to homeostasis (IRREVERSIBLE CHANGES) alleviation of symptoms pre-historic –19thcentury medicine focused on reducing the pain or other symptoms NO CAUSATIVE THERAPY PALLIATIVE THERAPY cardiovascular diseases genotype diet physical activity mental activity psycho-social activity biomarkers no clinical signs biomarkers clinical signs biomarkers clinical signs death ASYMPTOMATIC ≠ HEALTHY overweight/obesity, dyslipidemia, mild hypertension acute myocardial infarction, arrhythmia, hypertension heart failure (NYHA I-IV), cardiac death BIRTH DISEASE DEATH
  8. 8. OBESITY AND OVERWEIGHT ►how specific dietary compounds intake modulates the gene expression of the adipokines (nutrigenomics) ►interaction between specific dietary compoundand certain genetic polymorphisms by using Kohonen neural network (nutrigenomics and personalized medicine) new knowledge on food and gene interactions to design better diet protocols ANA PETELIN ANA PETELIN KATJA VENKO
  9. 9. OBESITY AND OVERWEIGHT ►Identification of early biomarkers of metabolic imbalance in healthy subjects ►bilirubin as a pre-disease biomarker in asymptomatic individuals ANA PETELIN LOVRO ŽIBERNA
  10. 10. CANCER AND LIFESTYLES “localadjuvanttherapy”byanthocyanins-enricheddietforcoloncancerpatients focusonmembranetransportersinvolvedinuptake(bilitranslocase)andefflux(multridrugresistanceproteins)inGIT JOVANA ČVOROVIĆ UROŠ RAJČEVIĆ morphologicalandproteomiccharacterizationoforganotypicspheroidsderivedfromcolorectalcancertissue
  11. 11. CANCER AND LIFESTYLES newhistologicalbiomarker(expressionofbilitranslocase)forthediagnosisofkidneycancer developmentofanti-bilitranslocasemonoclonalantibodies(diagnostictool) UROŠ RAJČEVIĆ LUIGINA DE LEO
  12. 12. NEURODEGENERATION large-scaletranscriptionalprofilingofbrainsfromprion-infectedmacaques,whichareanexcellentmodelforhumanpriondisorders identificationofpotentialdiseasebiomarkersandnovelpotentialtargetsfortherapeutics MAURA BARBISIN KATJA VENKO novelpredictivecomputationalmodel(artificialneuralnetworkmodel)fordesigningnewcompoundswithanti- prionactivitythatcanbefurtherexperimentallytestedusingcell-screeningassaypre-clinicalstudies
  13. 13. CARDIOVASCULAR DISEASES interventionalcardiologyiodinecontrast-inducednephropathy detectionofearlysignsofnephropathybyserumbiomarkerNGAL POLONA LIKAR MITJA MARTELANC POLONA LIKAR LOVRO ŽIBERNA pharmacologicalandnutraceuticalmodulationsofcontrast-inducedtoxicityonhumanvascularendothelialcells
  14. 14. COELIAC DISEASE doubleimmunofluorescenceanalysisallowedtheearlydiagnosisinsubjectsathighriskofceliacdisease pre-diseasediagnosis(earlydietmodificationleadstobetterprognosis) LUIGINA DE LEO LUIGINA DE LEO MORENA SILVESTRINI developmentofelectrochemicalbiosensorsforthedetectionofdifferentautoantibodies(e.g.,anti-tTG),anti- gliadin,anti-thyroidperoxidase(anti-TPO) involvedinceliacdiseaseandassociatedautoimmunediseases,directlyinbiologicalsamples newtechnology:electrochemicalimpedancespectroscopy
  15. 15. BONE HEALTH improvinglife-spanoforthopedicimplantsbythepreventionofprostheticjointinfections incorporation/immobilizationofantimicrobialpeptides(AMPs)intobiopolymericmatricesaspotentialcoatingsfororthopedicimplants. FRANJA ŠULEK FRANCESCA D’ESTE ALESSANDRO BALDAN correlationbetweenbloodbiomarkerKlothofactorandbonemineraldensity lowerKlotholevelsinperipheralbloodarelinkedtoosteopeniaandosteoporosisinthefemur
  16. 16. DIAGNOSTIC BIOMARKERS novelmethodforthedetectionoffreebilirubininhumanserum(non-routineclinicalmeasurementofthebioactiveform)–around10nMinhumanserum MITJA MARTELANC fast,cheapandeasy-tousesensingdevicesforthedetectionofmoleculesofclinicalimportance,directlyinbiologicalsamples improvedmethodfortotalandconjugatedbilirubindetectioninserumsamplesusinganovelbiosensorbasedonelectrochemicaldetection LOVRO ŽIBERNA MORENA SILVESTRINI
  17. 17. INTELLECTUAL PROPERTY  open innovation  “Think before you publish.”  “Perhaps, patent?”  creation of a necessary scientific bridge between a number of entities: - Universities; - Big industries; - Research centres; - Tech transfer offices; - The market; - Public institutions; - SMEs; - Laboratories • good connection improves the outputs of scientific research GIORGIA FAVARO IP BRIDGE Academic s Big industries Research Centres Tech Transfer Offices Market Public Insitution s SMEs Laborator ies
  18. 18. Trans2Care workpackages Embedding training in the network’s activitiesWP6TECH TRANSFER WP2 PREPARATORY ACTIVITY WP7 SUSTAINABILITY WP8 DISSEMINATION WP5 MAPPING & ROAD-MAPPING COORDINATION WP1 MANAGEMENT WP4 part 1 TECHNOLOGICAL TRAINING WP3 RECRUITMENT OF 14 RESEARCHERS WP4 part 2 COMPLEMENTARY TRAININGEVOLUTION OF HUMAN CAPITAL The 14 researchershavedonelargepartsofWP 6-8 8 WPs WP 6as the core WP 5,7,8 ancillary to WP6 Training: WP4 and transversal to WPs scientific research = technological training SCIENTIFIC COMMUNICATION
  19. 19. OTHER SCIENTIFIC ACTIVITIES Focus on knowledge sharing and developing integrated skills •acting as reviewers of original research manuscripts for SCI scientific journals •tutoring and co-mentorships of PhD and undergraduate students •submission of post-doctoral grant applications •active involvement in research discussion at online scientific forums •participation at online scientific webinars
  20. 20. Progetto Rete Transregionale per l ’ innovazione ed il Trasferimento Tecnologico per il Miglioramento della Sanità finanziato nell ’ambito del Programma per la Cooperazione Transfrontaliera Italia-Slovenia 2007-2013, dal Fondo europeo di sviluppo regionale e dai fondi nazionali. Projekt Transregionalno omrežje za inovacijo in prenos tehnološkega znanja za izboljšanje zdravstva sofinancirana v okviru Programa čezmejnega sodelovanja Slovenija-Italija 2007-2013 iz sredstev Evropskega sklada za regionalni razvoj in nacionalnih sredstev. Thank you for the attention ! Partners: LP – Università degli Studi di Trieste, PP1 – Kemijski Inštitut Ljubljana, PP1 – Kemijski Inštitut Ljubljana, PP2 – Scuola Internazionale Superiore di Studi Avanzati, PP3 – Univerza v Novi Gorici, PP4 – Università di Ferrara, PP5 – Treviso Tecnologia, PP6 – Splošna Bolnišnica Dr. Franca Derganca, PP7 – Università Ca’ Foscari di Venezia, PP8 – Università di Udine, PP9 – IRCCS Burlo Garofalo, PP10 – Zavod Republike Slovenije Za Transfuzijsko Medicino, PP11 – Ortopedska Bolnišnica Valdoltra, PP12 – Univerza na Primorskem - Fakulteta za Vede o Zdravju.

×